Table 3.
Lobular component | ||||||
---|---|---|---|---|---|---|
Case number | Age (year) | Clinical stage | Type | Grade | E/P/H | Size (cm) |
1 | 62 | I | ILC | 2 | +/−/− | 1 |
2 | 50 | I | ILC | 1 | +/+/− | 1 |
3 | 42 | I | ILC | 1 | +/+/− | 1.5 |
4 | 79 | I | ILC | 3 | +/−/− | 1.7 |
5 | 77 | I | ILC | 1 | +/−/− | 1.9 |
6 | 72 | I | ILC | 1 | +/−/− | 1.9 |
7 | 76 | IIA | ILC | 1 | +/+/− | 2.4 |
8 | 59 | IIA | ILC | 1 | +/+/− | 3 |
9 | 74 | IIA | ILC | 2 | +/−/− | 3 |
10 | 77 | IIA | ILC | 1 | +/+/− | 4 |
11 | 36 | IIB | ILC | 1 | +/+/− | 4 |
12 | 92 | IIB | ILC | 1 | +/+/− | 5.3 |
13 | 43 | IIB | ILC | 1 | +/+/− | 7 |
14 | 49 | IIIA | ILC | 1 | +/+/− | 8 |
Average | 63.4 | – | – | – | – | 3.3 |
E, estrogen receptor; H, human epidermal growth factor receptor 2 (HER2); ILC, invasive lobular carcinoma; P, progesterone receptor.